Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 4,477
Out of 4,814 analysts
7
Total ratings
n/a
Success rate
-59.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $0.12 | - | 3 | Dec 12, 2024 | |
| CVAC CureVac | Reiterates: Neutral | n/a | $3.14 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $0.51 | +1,664.71% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $6.78 | +150.74% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $24.73 | - | 1 | Apr 26, 2023 |
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.12
Upside: -
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.14
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $0.51
Upside: +1,664.71%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $6.78
Upside: +150.74%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $24.73
Upside: -